Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection

PLoS Neglected Tropical Diseases

Volumn 7, Issue 1, 2013, Pages

  Takele, Yegnasew ^a   Abebe, Tamrat ^b   Weldegebreal, Teklu ^a   Hailu, Asrat ^b   Hailu, Workagegnehu ^a   Hurissa, Zewdu ^a   Ali, Jemal ^a   Diro, Ermiyas ^a   Sisay, Yifru ^a   Cloke, Tom ^c   Modolell, Manuel ^d   Munder, Markus ^e   Tacchini Cottier, Fabienne ^f   Müller, Ingrid ^c   Kropf, Pascale ^g  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ARGINASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ARM CIRCUMFERENCE; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; LIVER SIZE; MALE; MIXED INFECTION; PARASITE LOAD; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN DETERMINATION; SPLEEN SIZE; UREA NITROGEN BLOOD LEVEL; VIRUS REPLICATION; VISCERAL LEISHMANIASIS;

EID: 84873508298     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001977     Document Type: Article

References (42)

1. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al. (2010) Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848-855.
2. (2006) Visceral leishmaniasis diagnosis & treatment guideline for health workers in Ethiopia. In: Ministry of Health E, editor. 1st Edition ed.
3. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
4. Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152-158.
5. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359 table of contents.
6. Bernier R, Turco SJ, Olivier M, Tremblay M, (1995) Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol 69: 7282-7285.
7. Zhao C, Papadopoulou B, Tremblay MJ, (2004) Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol 113: 81-88.
8. Mock DJ, Hollenbaugh JA, Daddacha W, Overstreet MG, Lazarski CA, et al. (2012) Leishmania Induces Survival, Proliferation and Elevated Cellular dNTP Levels in Human Monocytes Promoting Acceleration of HIV Co-Infection. PLoS Pathog 8: e1002635.
9. Lodge R, Ouellet M, Barat C, Andreani G, Kumar P, et al. (2012) HIV-1 promotes intake of Leishmania parasites by enhancing phosphatidylserine-mediated, CD91/LRP-1-dependent phagocytosis in human macrophages. PLoS ONE 7: e32761.
10. Wolday D, Akuffo H, Fessahaye G, Valantine A, Britton S, (1998) Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis 30: 29-34.
11. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, et al. (2003) Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41: 5080-5084.
12. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, et al. (1989) Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 84: 1892-1899.
13. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
14. Goto H, Prianti MG, (2009) Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 51: 241-246.
15. Cloke T, Garvery L, Choi BS, Abebe T, Hailu A, et al. (2010) Increased arginase activity correlates with disease severity in HIV seropositive patients. Journal of Infectious Diseases 202: 374-385.
16. Abebe T, Yegnasew T, Weldegebreal T, Cloke T, Closs E, et al. (Submitted for publication) Arginase: a marker of disease status in patients with visceral leishmaniasis.
17. Rodriguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
18. Bronte V, Zanovello P, (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654.
19. Munder M, (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158: 638-651.
20. Cloke T, Munder M, Taylor GP, Müller I, Kropf P (submitted for publication) Characterization of a novel population of low-density granulocytes associated with disease severity in HIV seropositive patients.
21. Chulay JD, Bryceson AD, (1983) Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479.
22. Abebe T, Hailu A, Woldeyes M, Mekonene W, Bilch K, et al. (2012) Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia. PLoS NTD 6: e1684.
23. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, et al. (2006) Decreased Expression of CD3 zeta and Nuclear Transcription Factor kappa B in Patients with Pulmonary Tuberculosis: Potential Mechanisms and Reversibility with Treatment. J Infect Dis 194: 1385-1393.
24. Munier ML, Kelleher AD, (2007) Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. Immunol Cell Biol 85: 6-15.
25. Boasso A, Shearer GM, Chougnet C, (2009) Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med 265: 78-96.
26. Wolday D, Berhe N, Britton S, Akuffo H, (2000) HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS 14: 921-929.
27. Shearer GM, Clerici M, (1991) Early T-helper cell defects in HIV infection. AIDS 5: 245-253.
28. Levy JA (2007) HIV and the pathogenesis of AIDS; press A, editor.
29. Appay V, Sauce D, (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214: 231-241.
30. Russo R, Laguna F, Lopez-Velez R, Medrano FJ, Rosenthal E, et al. (2003) Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 97 Suppl 1: 99-105.
31. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, et al. (2005) Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J 19: 1000-1002.
32. Schafer B, Hauber I, Bunk A, Heukeshoven J, Dusedau A, et al. (2006) Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity. J Infect Dis 194: 740-750.
33. Iniesta V, Gomez-Nieto, Corraliza I, (2001) The inhibition of Arginase by Nw-Hydroxy-L-Arginine controls the growths of Leishmania inside macrophages. J Exp Med 193: 777-783.
34. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, et al. (2009) Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Neglected Tropical Diseases 14: e480.
35. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, et al. (2005) Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105: 2549-2556.
36. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560.
37. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, et al. (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 37: 935-945.
38. Schmielau J, Finn OJ, (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61: 4756-4760.
39. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, et al. (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 184: 3284-3297.
40. Padilla H, Sanchez A, Powell RN, Umezawa C, Swendseid ME, et al. (1971) Plasma amino acids in children from Guadalajara with kwashiorkor. Am J Clin Nutr 24: 353-357.
41. Poeze M, Bruins MJ, Luiking YC, Deutz NE, (2010) Reduced caloric intake during endotoxemia reduces arginine availability and metabolism. Am J Clin Nutr 91: 992-1001.
42. Moyano D, Vilaseca MA, Artuch R, Lambruschini N, (1998) Plasma amino acids in anorexia nervosa. Eur J Clin Nutr 52: 684-689.